CAR-T Meeting 2024 | The development of CD79b-targeting CAR T-cells for the treatment of NHL
In patients who have relapsed following CD19 CAR-T therapy, loss of the CD19 antigen is often seen. This means an alternative antigen must be targeted in subsequent lines of treatment. In this video, Beatriz Martin Antonio, PhD, Fundación Jimenez Diaz, Madrid, Spain, discusses the development of novel CAR T-cells targetting CD79b for the treatment of non-Hodgkin lymphoma (NHL). These cells exhibited anti-lymphoma activity in vitro and in vivo in NHL models, and will as a result be investigated in a clinical trial. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
